





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449/PTO**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(Use as many sheets as necessary)*

Sheet 1 of 2 Attorney Docket Number 03-087-A

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
AM	1	US- 6,479,515 - B1	11-12-2002	Barth, et al.	3-102 651-2
AM	2	US- 6,384,222 - B1	05-07-2002	Barth, et al.	3-102 651-2

## FOREIGN PATENT DOCUMENTS

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 01.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8123 (1-800-786-8123) and request section B.

Substitute for form 1449/PTO				Complete if Known	
				Application No.	10/823,372
				Filing Date:	April 12, 2004
				First Named Inventor	Groneberg
				Art Unit	1625
				Examiner Name	Seaman, D. Margaret
Sheet	2	of	2	Attorney Docket Number	03-087-A

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
(DMS)	8	JESSELL et al., "Pain and Analgesia" in <u>Principles of Neural Science</u> , 3 <sup>rd</sup> Edition, 1991, E.R. Kandel, J.H. Schwartz, T.M. Jessell, editors, pp. 385-399.	
	9	M.J. MILLAN, "The Induction of Pain: An Integrative Review," <u>Prog. Neurobiol.</u> , 1999, 57:1-164.	
	10	REGOLI et al., "Pharmacology of Bradykinin and Related Kinins," <u>Pharmacological Rev.</u> , 1980, 32(1):1-46.	
	11	MENKE et al., "Expression Cloning of a Human B <sub>1</sub> Bradykinin Receptor," <u>J. Biol. Chem.</u> , 1994, 269:21583-21586.	
	12	HESS et al., "Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor," <u>Biochem. Biophys. Res. Commun.</u> , 1992, 184:260-268.	
	13	F. MARCEAU et al., "Kinin B <sub>1</sub> receptors: a review," <u>Immunopharmacology</u> , 1995, 30:1-26.	
	14	E.J. COREY et al., "Highly Enantioselective Borane Reduction of Ketones Catalyzed by Chiral Oxazaborolidines. Mechanism and Synthetic Implications," <u>J. Am. Chem. Soc.</u> , 1987, v. 109, pp. 5551-5553.	
	15	T. OHKUMA et al., "Practical Enantioselective Hydrogenation of Aromatic Ketones," <u>J. Am. Chem Soc.</u> , 1995, v. 117, pp. 2675-2676.	
(DMS)	16	THOMPSON et al., "Direct Conversion of Activated Alcohols to Azides Using Diphenyl Phosphoroazidate. A Practical Alternative to Mitsunobu Conditions," <u>J. Org. Chem.</u> , 1993, 58 (22):5886-5888.	

Examiner Signature		Date Considered	5/19/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.